Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis: A Case Study. Issue 1 (28th January 2022)

• Record Type: Journal Article
• Authors: Winbush, Angelina; Alpizar-Rivas, Rodolfo; Gupta, Purba; Zanoria, Catherine; Chuang, Sally; Prasad, Paritosh; Louie, Ted
• Is Part Of: Infectious diseases in clinical practice. Volume 30:Issue 1(2022)
• Publication Date: 2022-01-28
• Subjects: dalbavancin -- oritavancin -- endotipsitis -- TIPS -- long-acting lipoglycopeptide -- cirrhosis; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Periodicals; Electronic journals; 616.9
• DOI: 10.1097/IPC.0000000000001082
• Languages: English
• ISSNs: 1056-9103

Abstract

Abstract: Endovascular Staphylococcal infections involving prosthetic material typically require long courses of intravenous antibiotics, which are often completed at home or in a rehabilitation facility with outpatient parenteral antibiotic therapy. An alternative to outpatient parenteral antibiotic therapy is the use of long-acting lipoglycopeptides (LaLGPs). Dalbavancin and oritavancin are LaLGPs that have been used for the treatment of catheter-related blood-stream infections and endocarditis. However, their use in patients with liver dysfunction is not well documented in the literature. Herein, we describe a case of LaLGPs used to successfully treat endotipsitis, an infection of the transjugular intrahepatic portosystemic shunt system, in a patient with cirrhosis.